Emcure Pharmaceuticals has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) following an inspection of its formulations manufacturing facility in Sanand, Ahmedabad, Gujarat.
The USFDA conducted this inspection from May 06, 2026 to May 15, 2026. The USFDA has classified the inspection status of the said facility as Voluntary Action Indicated (VAI) and accordingly, the inspection stands closed.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
